Calgary, Alberta – TheNewswire - July 22, 2024 - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in vision enhancement technology, is pleased to announce that its intraocular lenses are now being manufactured for the upcoming first-in-human study in the Dominican Republic.

“We are thrilled to collaborate with Bioana, leveraging their medical device expertise and cutting-edge manufacturing facilities to bring our innovative intraocular lenses to life,” said Dean Burns, CEO of Ocumetics Technology Corp.  “Producing these lenses is a critical milestone in our mission to provide clear distance and near vision after cataract surgery.”

The Ocumetics lenses promise groundbreaking enhancements to vision correction technology. Designed to provide excellent visual acuity at all distances and improved quality of life for patients, these lenses are set to be evaluated in an upcoming first-in-human clinical study in the Dominican Republic.

Bioana’s state-of-the-art design expertise, manufacturing capabilities and commitment to excellence align perfectly with Ocumetics’ dedication to developing top-tier accommodating intraocular lenses. The initial production run will support the clinical evaluation process, providing essential data to ensure the safety and efficacy of the Ocumetics lens.

“We are honored to be selected by Ocumetics for this pivotal project,” said Adriana Torres COO and Chief Engineer at Bioana, a premier design and development firm in Monterrey, Mexico.  “Our team is excited to apply our extensive experience in medical device manufacturing to help Ocumetics achieve their vision of transforming eye care.”

The first-in-human study in the Dominican Republic is a crucial step toward bringing these innovative lenses to market. The study will evaluate the performance of the Ocumetics lenses in a clinical setting, providing valuable data, as Ocumetics works to obtain regulatory clearance for its accommodating intraocular lenses.

For more information about Ocumetics Technology Corp. and our cutting-edge vision enhancement solutions, please visit Ocumetics.com.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near.  

About Bioana

Bioana is a leading design and development company based in Monterrey, Mexico, specializing in the production of medical devices.  With a strong commitment to quality and innovation, Bioana partners with global companies to bring cutting-edge medical solutions to market.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns                                Dayton Marks

President and CEO                        Director

(817) 874-7564                                (778) 347-2500

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.